1. The Ca~v~2.3 Voltage-Gated Ca^2+^ Channel
============================================

Ca~v~2.3 belongs to the family of voltage-gated Ca^2+^ channels which comprises ten different genes for ion conducting pore proteins ([Figure 1](#pharmaceuticals-06-00759-f001){ref-type="fig"}). The ion conducting pore protein of the Ca~v~2.3 VGCCs was initially cloned from a rabbit brain cDNA library \[[@B1-pharmaceuticals-06-00759]\]. After functional expression of the rat Ca~v~2.3 clone, it was initially speculated that it may represent the low voltage-activated T-type Ca^2+^ channel, which was not yet structurally identified at that time \[[@B2-pharmaceuticals-06-00759]\]. However, consecutive cloning and expression of human Ca~v~2.3 splice variants in *X. laevis* oocytes or HEK-293 cells revealed a VGCC with properties closer resembling a high-voltage-gated Ca^2+^ channel \[[@B3-pharmaceuticals-06-00759],[@B4-pharmaceuticals-06-00759]\].

![Evolutionary tree of voltage-gated Ca^2+^ channels (modified according to \[[@B5-pharmaceuticals-06-00759]\]). The cDNA of the putative membrane-spanning regions including the pore loops of the human sequences were aligned.](pharmaceuticals-06-00759-g001){#pharmaceuticals-06-00759-f001}

Although the structure of Ca~v~2.3 deduced from sequencing of cDNA has now been known for several years \[[@B6-pharmaceuticals-06-00759],[@B7-pharmaceuticals-06-00759]\], its physiological and patho­physiological roles are far from fully understood \[[@B8-pharmaceuticals-06-00759],[@B9-pharmaceuticals-06-00759],[@B10-pharmaceuticals-06-00759]\]. Evolutionarily, Ca~v~2.3 may have developed very early \[[@B5-pharmaceuticals-06-00759],[@B11-pharmaceuticals-06-00759]\], which may underline its great significance *in vivo*. The total quaternary structure of a Ca~v~2.3-containing native VGCC is still unknown, but may contain additional subunits including the well known auxiliary β-subunits, which have been shown to modulate Ca~v~2.3-mediated inward currents in heterologous expression systems \[[@B12-pharmaceuticals-06-00759],[@B13-pharmaceuticals-06-00759]\]. Molecular properties of Ca~v~2.3 have been characterized on the amino acid level for functional protein-protein interaction \[[@B14-pharmaceuticals-06-00759],[@B15-pharmaceuticals-06-00759],[@B16-pharmaceuticals-06-00759]\] however to date, Ca~v~2.3 VGCCs have yet to be purified as has been done for L-type Ca^2+^ channels from rabbit skeletal muscle \[[@B17-pharmaceuticals-06-00759],[@B18-pharmaceuticals-06-00759],[@B19-pharmaceuticals-06-00759],[@B20-pharmaceuticals-06-00759]\], and bovine heart \[[@B21-pharmaceuticals-06-00759]\] and for the neuronal N-type Ca^2+^ channels \[[@B22-pharmaceuticals-06-00759],[@B23-pharmaceuticals-06-00759]\].

Sequence comparison of the deduced primary sequence revealed the well known intramolecular homology pattern, which is known for all voltage-gated Ca^2+^ as well as for voltage-gated Na^+^ channels. It contains four internal repeats, which have been termed domains I, II, III, and IV. Secondary structure analysis predicts 6 transmembrane segments including a random coiled short part between transmembrane segment 5 and 6, the pore forming segment (P-loop) \[[@B24-pharmaceuticals-06-00759]\]. Many of these structure predictions resemble the confirmed structural elements in the bacterial and rat voltage-gated K^+^-channel \[[@B25-pharmaceuticals-06-00759],[@B26-pharmaceuticals-06-00759]\] and a bacterial Na^+^-channel \[[@B27-pharmaceuticals-06-00759],[@B28-pharmaceuticals-06-00759]\].

Additional elements may contribute to the kinetic properties of Ca~v~2.3-mediated inward currents as reported for structurally similar ion channels. The segments S6 participate in gating the ion channels \[[@B29-pharmaceuticals-06-00759],[@B30-pharmaceuticals-06-00759],[@B31-pharmaceuticals-06-00759],[@B32-pharmaceuticals-06-00759]\], and the P-loops form essential parts of the selectivity filters, thereby also influencing the speed of the ion flux through the pore \[[@B33-pharmaceuticals-06-00759],[@B34-pharmaceuticals-06-00759],[@B35-pharmaceuticals-06-00759],[@B36-pharmaceuticals-06-00759],[@B37-pharmaceuticals-06-00759],[@B38-pharmaceuticals-06-00759],[@B39-pharmaceuticals-06-00759],[@B40-pharmaceuticals-06-00759]\]. The segment S4 acts mainly as the voltage sensor \[[@B41-pharmaceuticals-06-00759],[@B42-pharmaceuticals-06-00759]\], and its detailed orientation to the pore region has been elucidated in crystals from the bacterial K^+^ channel to a great extent \[[@B43-pharmaceuticals-06-00759]\].

Only segments of the cytosolic loops from Ca~v~1.2 L-type VGCCs have been co-crystallized with functionally auxiliary subunits \[[@B44-pharmaceuticals-06-00759]\] or functionally interacting calmodulin \[[@B45-pharmaceuticals-06-00759],[@B46-pharmaceuticals-06-00759],[@B47-pharmaceuticals-06-00759],[@B48-pharmaceuticals-06-00759]\]. Few protein interactions of Ca~v~2.3 have been reported such as with a β-subunit \[[@B15-pharmaceuticals-06-00759],[@B16-pharmaceuticals-06-00759]\] or with novel partners in heterologous expression systems \[[@B49-pharmaceuticals-06-00759],[@B50-pharmaceuticals-06-00759],[@B51-pharmaceuticals-06-00759],[@B52-pharmaceuticals-06-00759]\], however, they have yet to be investigated by crystallization. The β-subunit interaction site with Ca~v~1.1 and Ca~v~1.2 is located in a conserved region between domain I and II \[[@B53-pharmaceuticals-06-00759],[@B54-pharmaceuticals-06-00759]\], which also contains the inter­action site of Ca~v~2.3 with β-subunits \[[@B14-pharmaceuticals-06-00759],[@B15-pharmaceuticals-06-00759],[@B16-pharmaceuticals-06-00759]\].

The II-III linker harbors a unique site located within the arginine-rich stretch, which is responsible for Ca^2+^-mediated modulation of the Ca~v~2.3 voltage-gated Ca^2+^ channel \[[@B55-pharmaceuticals-06-00759]\]. It may be involved in the protein kinase C (PKC)-mediated signaling to Ca~v~2.3 \[[@B56-pharmaceuticals-06-00759]\], linking Ca~v~2.3 signaling to muscarinic receptor activation \[[@B57-pharmaceuticals-06-00759],[@B58-pharmaceuticals-06-00759],[@B59-pharmaceuticals-06-00759],[@B60-pharmaceuticals-06-00759],[@B61-pharmaceuticals-06-00759]\] and perhaps also to muscarinic enhancement of the "toxin-resistant" R-type Ca^2+^ current in hippocampal CA1 pyramidal neurons \[[@B62-pharmaceuticals-06-00759]\]. Ca~v~2.3 also contains the better known, carboxyterminal Ca^2+^/calmodulin interaction site, which was not only found for the members of the Ca~v~2/non-L-type but also for members of the classical L-type Ca^2+^ channel subfamily \[[@B63-pharmaceuticals-06-00759]\].

Structurally, a broad set of splice variants can be predicted from the different cloning approaches ([Table 1](#pharmaceuticals-06-00759-t001){ref-type="table"}), which result from alternate use of exon 19 encoded arginine-rich segment in the II-III loop, as well as from the alternate use of exon 45 in the carboxyterminal region \[[@B7-pharmaceuticals-06-00759]\]. Ca~v~2.3d was originally cloned as a fetal splice variant from human brain \[[@B4-pharmaceuticals-06-00759]\]. Interestingly, the major splice variants ([Table 2](#pharmaceuticals-06-00759-t002){ref-type="table"}) deduced from RT-PCR studies differ between brain regions \[[@B64-pharmaceuticals-06-00759]\] in mice. Splice variants of Ca~v~2.3 from different species (see also [Table 1](#pharmaceuticals-06-00759-t001){ref-type="table"}, [Table 2](#pharmaceuticals-06-00759-t002){ref-type="table"}) as well as auxiliary subunits are tissue-specifically expressed \[[@B9-pharmaceuticals-06-00759]\]. In addition to expression in neuronal \[[@B65-pharmaceuticals-06-00759],[@B66-pharmaceuticals-06-00759],[@B67-pharmaceuticals-06-00759],[@B68-pharmaceuticals-06-00759],[@B69-pharmaceuticals-06-00759]\] and endocrine tissues \[[@B70-pharmaceuticals-06-00759],[@B71-pharmaceuticals-06-00759],[@B72-pharmaceuticals-06-00759],[@B73-pharmaceuticals-06-00759],[@B74-pharmaceuticals-06-00759],[@B75-pharmaceuticals-06-00759],[@B76-pharmaceuticals-06-00759],[@B77-pharmaceuticals-06-00759],[@B78-pharmaceuticals-06-00759],[@B79-pharmaceuticals-06-00759],[@B80-pharmaceuticals-06-00759],[@B81-pharmaceuticals-06-00759],[@B82-pharmaceuticals-06-00759],[@B83-pharmaceuticals-06-00759],[@B84-pharmaceuticals-06-00759],[@B85-pharmaceuticals-06-00759]\], Ca~v~2.3 transcripts have also been detected in mamalian heart \[[@B86-pharmaceuticals-06-00759],[@B87-pharmaceuticals-06-00759],[@B88-pharmaceuticals-06-00759]\], kidney \[[@B70-pharmaceuticals-06-00759],[@B86-pharmaceuticals-06-00759],[@B89-pharmaceuticals-06-00759]\], sperm \[[@B90-pharmaceuticals-06-00759],[@B91-pharmaceuticals-06-00759],[@B92-pharmaceuticals-06-00759],[@B93-pharmaceuticals-06-00759]\], spleen \[[@B3-pharmaceuticals-06-00759]\], and retina \[[@B94-pharmaceuticals-06-00759],[@B95-pharmaceuticals-06-00759],[@B96-pharmaceuticals-06-00759],[@B97-pharmaceuticals-06-00759]\]. Furthermore, the subcellular distribution of Ca~v~2.3 has been investigated revealing both somatodendritic and presynaptic expression \[[@B98-pharmaceuticals-06-00759]\] with additional functional specificities \[[@B99-pharmaceuticals-06-00759]\].
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###### 

Splice variants of voltage-gated Ca~v~2.3 R-type Ca^2+^ channels. Exon 19 is encoding an arginine-rich segment of the cytosolic loop between domain II and III, which is responsible for a transient positive Ca^2+^ feedback, when cytosolic Ca^2+^ is in­creasing by Ca^2+^ influx through the channel itself. Exon 45 is encoding a carboxy­terminal insertion of unknown function. Details of exon 20 sequence are found in \[[@B7-pharmaceuticals-06-00759]\].

  Nomenclature, splice variant   Structure related to alternate exons expressed (+)   Expression (tissue and species)   Ref.                                  
  ------------------------------ ---------------------------------------------------- --------------------------------- ------ ---- ------------------------- ----------------------------------------------------------------------
  Ca~v~2.3a                      alpha1E-1                                            \-                                \+     \-   Rat cerebellum            \[[@B100-pharmaceuticals-06-00759]\]
  Ca~v~2.3b                      alpha1E-2                                            \+                                \-     \-   Less important in CNS     \[[@B3-pharmaceuticals-06-00759]\]
  Ca~v~2.3c                      alpha1E-3                                            \+                                \+     \-   Dominant in CNS           \[[@B3-pharmaceuticals-06-00759]\]
  Ca~v~2.3d                      alpha1Ed                                             \+                                \+     \+   Human fetal brain         \[[@B4-pharmaceuticals-06-00759]\]
  Ca~v~2.3e                      alpha1Ee                                             \-                                \+     \+   Pancreas, kidney, heart   \[[@B70-pharmaceuticals-06-00759],[@B101-pharmaceuticals-06-00759]\]
  Ca~v~2.3f                      alpha1Ef                                             \+                                \-     \+   Rat cerebellum            \[[@B100-pharmaceuticals-06-00759]\]
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Transcripts of major splice variants of voltage-gated Ca~v~2.3 R-type Ca^2+^ channels expressed in different brain regions \[[@B64-pharmaceuticals-06-00759]\].

  Brain region (mouse)                           Major splice variant   Miscellaneous
  ---------------------------------------------- ---------------------- ------------------------------------------------
  Neocortex                                      Ca~v~2.3c              Minor amounts of Ca~v~2.3e
  Hippocampus                                    Ca~v~2.3c              Minor amounts of Ca~v~2.3e
  Thalamus                                       Ca~v~2.3c              Substantial amounts of Ca~v~2.3e and Ca~v~2.3f
  Cerebellum, mesencephalon, medulla oblongata   Ca~v~2.3e              minor amounts of Ca~v~2.3a

In heterologous expression systems, Ca~v~2.3c \[[@B3-pharmaceuticals-06-00759]\] and Ca~v~2.3d \[[@B4-pharmaceuticals-06-00759],[@B102-pharmaceuticals-06-00759]\] inward currents are activated at test potentials of about −30 mV. The single channel conductance is about 14 pS \[[@B103-pharmaceuticals-06-00759]\], and the channel kinetics measured by patch-clamp recordings reveal a fast activating and inactivating channel type with transient inward current characteristics \[[@B7-pharmaceuticals-06-00759],[@B55-pharmaceuticals-06-00759]\], similar but not as fast as observed for T-type voltage-gated Ca^2+^ channels \[[@B13-pharmaceuticals-06-00759]\].

2. Selective and Non-Selective Antagonists of Ca~v~2.3
======================================================

The first "pharmacoresistant" Ca^2+^ current in vivo was recorded and published in 1993 \[[@B104-pharmaceuticals-06-00759],[@B105-pharmaceuticals-06-00759]\], which means it occured between the years 1987 (the first cloning of a VGCC subunit \[[@B106-pharmaceuticals-06-00759]\]) and 1994 (final cloning of the remaining high-voltage gated Ca^2+^ channels). Doe-1, cloned from *Discopyge ommata*, represented a novel Ca^2+^ channel type, which was insensitive towards dihydropyridines, but was antagonized rather than activated by 5 µM Bay K. This chan­nel type was only slightly and readily reversibly inhibited by 5 µM ω-conotoxin-MVIIC, was insensitive towards ω-agatoxin-IVA, and fully reversibly blocked by ω-conotoxin-GVIA, an irreversible antagonist of N-type Ca^2+^ channels \[[@B104-pharmaceuticals-06-00759]\]. Interestingly, the same group identified a similar Ca^2+^ current component in rat cerebellar granule neurons and called the doe-1-like component "R-type current" \[[@B105-pharmaceuticals-06-00759]\].

The peptide antagonist SNX-482, which was initially purified from the venom of the tarantula *Hysterocratis gigas* \[[@B107-pharmaceuticals-06-00759]\] blocks Ca~v~2.3 with an IC~50~ value of 15--30 nM and was the first and still is the only Ca~v~2.3-prevalent antagonist,. At concentrations higher than 500 nM SNX-482 also inhibits N-type Ca^2+^ currents \[[@B107-pharmaceuticals-06-00759]\], wherease L-type Ca^2+^ currents are inhibited by about 25% at concentrations of 200 nM SNX-482 \[[@B108-pharmaceuticals-06-00759]\]. Therefore, it only can be regarded as Ca~v~2.3-prevalent, but not as Ca~v~2.3-specific or -selective.

In cerebellar granule cells, two Ca~v~2.3 isoforms could be distinguished from eachother by their varying SNX-482 IC~50~ values of 6 nM and 81 nM, and a third R-type Ca^2+^ current component by its insensitivity to SNX-482 \[[@B109-pharmaceuticals-06-00759]\].

The first gene inactivation of Ca~v~2.3 led to knock-out mice, which in cerebellar granule cells and in DRG neurons still expressed a drug insensitive Ba^2+^ current. The peak inward current (I~Ba~) was even larger than in cultured mouse neurons from contol mice (knock-out I~Ba~ 113 ± 27 pA (n = 5 ); control 85 ± 21 pA (n = 9)) \[[@B110-pharmaceuticals-06-00759]\]. Only the wild type cultured neurons were inhibited by SNX-482, but not the neurons from Ca~v~2.3-deficient mice, leading to the conclusion that a non-Ca~v~2.3-dependent R-type current may exist.

In murine hippocampal and neocortical neurons, Ca~v~2.3 contributes not only to the SNX-482-sensitive component of the R-type Ca^2+^ current, which was recorded in the presence of combination of Ca^2+^ channel antagonists (ω-conotoxin-GVIA, 2 µM; ω-conotoxin-MVIIC, 3 µM; ω-agatoxin-IVA, 200 nM; nifedipine, 10 µM), but also to the SNX-482-insensitive part \[[@B66-pharmaceuticals-06-00759]\]. Interestingly, the voltage of half-maximal activation (V~1/2,\ act~) was shifted to more positive voltages in all three cell types investigated (dissociated CA1 pyramidal cells, dentate gyrus cells, neocortical neurons), specially in the neocortex, where it was reduced from --68 ± 2 mV to --58 ± 7 mV \[[@B66-pharmaceuticals-06-00759]\]. Overall, it may be useful to keep in mind that the R-type Ca^2+^ current may be more than only the Ca~v~2.3-gene encoded Ca^2+^ channel in neuronal tissues \[[@B8-pharmaceuticals-06-00759],[@B111-pharmaceuticals-06-00759],[@B112-pharmaceuticals-06-00759]\].

Divalent and trivalent heavy metal cations were often used to antagonize either all voltage-gated Ca^2+^ inward currents (Cd^2+^, La^3+^) or to specifially inhibit some T-type and the R-type Ca^2+^ current (Ni^2+^). Unfortunately, the half maximal concentrations for Ca~v~2.3 and Ca~v~3.2 are close to each other (10--30 µM), rendering Ni^2+^ blockade unsuitable for distinction of Ca~v~2.3 currents in tissue in which Ca~v~3.2 is also expressed. Physiologically, homeostasis of other divalent cations like Cu^2+^ and Zn^2+^ may play an important role \[[@B10-pharmaceuticals-06-00759],[@B113-pharmaceuticals-06-00759],[@B114-pharmaceuticals-06-00759]\], notably also in neurodegenerative disease \[[@B115-pharmaceuticals-06-00759]\].

[Table 3](#pharmaceuticals-06-00759-t003){ref-type="table"} summarizes the effect of drugs and toxins on Ca~v~2.3 reported in the literature. Most drugs in the table are non-selective, in the sense that currents through other Ca^2+^ channel Ca~v~α1 subunits are also antagonized with an IC~50~ not larger than tenfold. Many substances show inhibitory effects on Ca~v~2.3 or on R-type Ca^2+^ currents. One set of drugs is related to anticonvulsive effects, others are used as anesthetic drugs. Even high concentrations of classical Ca^2+^ channel antagonists can inhibit Ca~v~2.3 induced inward currents as shown for the dihydropyrdines isradipine \[[@B87-pharmaceuticals-06-00759]\] and nicardipine \[[@B116-pharmaceuticals-06-00759]\]. Routinely, in order to block L-type voltage-gated Ca^2+^ channels, a dihydropyridine concentration of around 10 µM is chosen by electrophysiologists. Considering that such high concentrations of isradipine or nicardipine substantially block E-/R-type Ca^2+^ currents, lower concentrations of e.g., isradipine of 0.5 µM are more suitable, in order to observe antagonism by low concentrations of SNX-482 as shown for cardiac E-/R-type Ca^2+^ currents in murine myocytes \[[@B101-pharmaceuticals-06-00759]\]. However, one has to keep in mind that SNX-482 may block L-type Ca^2+^ current at elevated concentrations \[[@B108-pharmaceuticals-06-00759]\].

3. Physiological Functions, in Which Ca~v~2.3 may be Involved, as Deduced from Ca~v~2.3-Deficient Mice
======================================================================================================

Many of the experimental results from gene-inactivated mice cannot automatically transferred to human physiology and pathophysiology of human diseases. But some basic conclusions may be drawn from these investigations of Ca~v~2.3-deficient mice, which were generated and analysed in several different laboratories (for detail, see Kamp *et al*. \[[@B8-pharmaceuticals-06-00759]\]).

Ca~v~2.3 is expressed in many regions of the CNS and also in peripheral organs and tissues, which makes it difficult to explore its full function in vivo. Ca~v~2.3 triggers or participates in the release of several neurotransmitters such as dopamine in the substantia nigra \[[@B117-pharmaceuticals-06-00759]\]. In the hippocampus Ca~v~2.3 contributes to fast glutamatergic transmission \[[@B118-pharmaceuticals-06-00759]\], where it is also involved in long term potentiation at the mossy fiber -- CA3 synapses. Therefore, Ca~v~2.3 participates in basic processes related to learning and memory formation \[[@B67-pharmaceuticals-06-00759],[@B119-pharmaceuticals-06-00759],[@B120-pharmaceuticals-06-00759],[@B121-pharmaceuticals-06-00759]\]. Furthermore, Ca~v~2.3 is an important regulator in spines: activation of Ca~v~2.3 triggers opening of small conductance Ca^2+^-activated K^+^-channels in CA1 hippocampal pyra­midal neurons \[[@B122-pharmaceuticals-06-00759],[@B123-pharmaceuticals-06-00759],[@B124-pharmaceuticals-06-00759]\], suggesting spine-restricted local microdomains, which are important for synaptic signalling \[[@B125-pharmaceuticals-06-00759]\]. R-type Ca^2+^ currents, which were recorded as Ni^2+^-sensitive tail currents, are available at resting potential and contribute to after-depolarization, and thus to the initiation of burst firing in CA1 hippocampal neurons \[[@B126-pharmaceuticals-06-00759]\].

pharmaceuticals-06-00759-t003_Table 3
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Selected antagonists of Ca~v~2.3 (modified according to: Wrubel, 2009 \[[@B127-pharmaceuticals-06-00759]\]). Recombinant Ca~v~2.3 was expressed in different cell lines and was cotransfected with auxiliary subunits (β-subunits from different species). Note, trace metals must be applied under well defined conditions, which provide buffering of the cation of interest \[[@B10-pharmaceuticals-06-00759]\]. Abbreviations: n.t. = not tested.

  Substance                          Application                               IC~50~ or K~d~ \[µM\]   Amount of max. Inhibition   Selectivity          Ref.
  ---------------------------------- ----------------------------------------- ----------------------- --------------------------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNX-482                            Peptide toxin                             0.015--0.030            \> 80 %                     Ca~v~2.3-prevalent   \[[@B107-pharmaceuticals-06-00759],[@B108-pharmaceuticals-06-00759],[@B128-pharmaceuticals-06-00759],[@B129-pharmaceuticals-06-00759],[@B130-pharmaceuticals-06-00759]\]
  ω-Aga-IVA                          Peptide toxin                             0.051                   80%                         non-selective        \[[@B116-pharmaceuticals-06-00759]\]
  ω-Aga-IIIA                         Peptide toxin                             0.003--0.010            100%                        non-selective        \[[@B107-pharmaceuticals-06-00759]\]
  Ni^2+^                             Unphysiological                           27.4/303                100%                        non-selective        \[[@B3-pharmaceuticals-06-00759],[@B131-pharmaceuticals-06-00759]\]
  Cd^2+^                             Unphysiological                           0.8                     100%                        non-selective        \[[@B3-pharmaceuticals-06-00759]\]
  Zn^2+^                             Trace element                             31.8                    \>90%                       non-selective        \[[@B132-pharmaceuticals-06-00759]\]
  Zn^2+^ (calibrated)                Trace element                             1.3                     100%                        non-selective        \[[@B10-pharmaceuticals-06-00759]\]
  Cu^2+^                             Trace element                             0.018                   100%                        non-selective        \[[@B10-pharmaceuticals-06-00759]\]
  Topiramate                         Anticonvulsive                            50.9                    \>70%                       non-selective        \[[@B133-pharmaceuticals-06-00759]\]
  Lamotrigine                        Anticonvulsive                            \>10                                                non-selective        \[[@B134-pharmaceuticals-06-00759]\]
  Sipatrigine                        Anticonvulsive                            10                      100%                        non-selective        \[[@B134-pharmaceuticals-06-00759]\]
  202W92                             Anticonvulsive                            56                      100%                                             \[[@B134-pharmaceuticals-06-00759]\]
  Ethosuximide                       Anticonvulsive                            20000                   100%                        non-selective        \[[@B135-pharmaceuticals-06-00759]\]
  MPS (α-methyl­phenylsuccinimide)   Anticonvulsive                            2300                    100%                                             \[[@B135-pharmaceuticals-06-00759]\]
  Phenytoin                          Anticonvulsive                            360                     100%                                             \[[@B135-pharmaceuticals-06-00759]\]
  Phenobarbital                      Anticonvulsive                            2700                    \>80%                                            \[[@B135-pharmaceuticals-06-00759]\]
  Pentobarbital                      Anticonvulsive                            600                     100%                                             \[[@B135-pharmaceuticals-06-00759]\]
  Halothane                          Inhalation anaesthetic                                                                                             \[[@B136-pharmaceuticals-06-00759],[@B137-pharmaceuticals-06-00759]\]
  Isoflurane                         Inhalation anaesthetic                    206                     100%                                             \[[@B136-pharmaceuticals-06-00759],[@B138-pharmaceuticals-06-00759],[@B139-pharmaceuticals-06-00759]\]
  Fomocaine                          Local anaestetic                          95                      100%                                             \[[@B140-pharmaceuticals-06-00759]\]
  Procaine                           Local anaestetic                                                                                                   \[[@B140-pharmaceuticals-06-00759]\]
  Octanol                            Organic solvent                           206                     100%                                             \[[@B135-pharmaceuticals-06-00759]\]
  (+)-ACN                            Steroid anaestetic                        5.3--10.2               100%                                             \[[@B141-pharmaceuticals-06-00759]\]
  (+)-ECN                            Steroid anaestetic                        9.9--16.1               \>70%                                            \[[@B141-pharmaceuticals-06-00759]\]
  Flecainide                         Antiarrhythmic                            320                                                                      \[[@B140-pharmaceuticals-06-00759]\]
  Penfluridol                        Antipsychotic                             13                                                                       \[[@B140-pharmaceuticals-06-00759]\]
  Verapamil                          Antihypertensive                          100                     100%                        non-selective        \[[@B142-pharmaceuticals-06-00759]\]
  Diltiazem                          Antihypertensive                          220                     100%                        non-selective        \[[@B4-pharmaceuticals-06-00759],[@B142-pharmaceuticals-06-00759]\]
  Isradipine                         Antihypertensive                          9.1                     100%                        non-selective        \[[@B87-pharmaceuticals-06-00759]\]
  Nicardipine                        Antihypertensive                          1                       n.t.                        non-selective        \[[@B116-pharmaceuticals-06-00759]\]
  Mibefradil                         Antihypertensive                          0.4/6.5                 100%                        non-selective        \[[@B143-pharmaceuticals-06-00759]\]
  Amiloride                          Diuretic                                  7400                    100%                        non-selective        \[[@B135-pharmaceuticals-06-00759]\]
  Ethoxyzolamide                     Carboanhydrase inhibitor/anticonvulsive   1                       70%                                              \[[@B144-pharmaceuticals-06-00759]\]
  Eugenol                            Analgetic                                                                                                          \[[@B145-pharmaceuticals-06-00759]\]
  Bisphenol A                        Environmental pollutant                   26                      50%                         non-selective        \[[@B146-pharmaceuticals-06-00759]\]

The existance of a fetal brain Ca~v~2.3 isoform \[[@B4-pharmaceuticals-06-00759]\] and the changes in expression of Ca~v~2.3 during neuronal development point to an important role of Ca~v~2.3 during early prenatal stages \[[@B147-pharmaceuticals-06-00759],[@B148-pharmaceuticals-06-00759],[@B149-pharmaceuticals-06-00759]\]. At nerve terminals of the calyx of Held, N- and R-type Ca^2+^ channels are replaced by P-/Q-type Ca^2+^ channels during development \[[@B150-pharmaceuticals-06-00759]\].

Ca~v~2.3-deficient mice reveal altered pain response \[[@B151-pharmaceuticals-06-00759]\], and transcripts of two different splice variants of Ca~v~2.3 could be identified in rat nociceptive neurons \[[@B152-pharmaceuticals-06-00759]\]. The major splice variant was Ca~v~2.3e, which was also detected in the cerebellum, heart and endocrine system ([Table 1](#pharmaceuticals-06-00759-t001){ref-type="table"}, [Table 2](#pharmaceuticals-06-00759-t002){ref-type="table"}).

Ca~v~2.3 is highly expressed in the amygdala, in which the R-type Ca^2+^ current represents the largest component of high-voltage gated Ca^2+^ currents. Ca~v~2.3-deficient mice exhibited signs of enhanced fear assuming that Ca~v~2.3-based R-type Ca^2+^ currents in the amygdala may be associated with fear \[[@B153-pharmaceuticals-06-00759]\].

Ca~v~2.3-deficient mice represent an important model for convulsive and non-convulsive seizures as was summarized in \[[@B9-pharmaceuticals-06-00759]\]. Based on the initial detection of Ca~v~2.3 transcripts in the insulinoma cell line INS-1 \[[@B70-pharmaceuticals-06-00759],[@B73-pharmaceuticals-06-00759]\], additional investigations were performed with Ca~v~2.3-deficient mice, which showed disturbance not only of glucose-induced insulin release \[[@B72-pharmaceuticals-06-00759],[@B75-pharmaceuticals-06-00759]\], but also of glucose-mediated glucagon suppression \[[@B74-pharmaceuticals-06-00759]\], and more important even disturbances of glucose-mediated somatostatin-release \[[@B80-pharmaceuticals-06-00759]\].

SNX-482 sensitive R-type Ca^2+^ current was related to the release of gonadotropin-releasing hormone \[[@B81-pharmaceuticals-06-00759]\] and of oxytocin \[[@B76-pharmaceuticals-06-00759],[@B77-pharmaceuticals-06-00759]\]. Overall, peptide hormone release often appears to be triggered by Ca~v~2.3 VGCCs, possibly by producing the global increase in cytoxolic Ca^2+^ required for refilling of the readily releasable pool of granules during the second phase of insulin release \[[@B75-pharmaceuticals-06-00759],[@B154-pharmaceuticals-06-00759]\].

After cerebral aneurysm rupture and subarachnoidal hemorrhage Ca~v~2.3 has been shown to contribute to cerebral artery constriction *i.e.*, vasospasm \[[@B155-pharmaceuticals-06-00759]\], a devastating delayed event causing often fatal strokes. Accordingly intracisternal administration of SNX-482 reduced delayed vasospasm in a rat model of subarachnoid hemmorhage \[[@B156-pharmaceuticals-06-00759]\].

The expression of Ca~v~2.3 in cardiomyocytes is still under discussion: Ca~v~2.3 protein has yet to be detected reliably in murine cardiomyocytes, but transcripts could be amplified by single cell RT-PCR from microscopically identified murine cardiomyocytes \[[@B87-pharmaceuticals-06-00759],[@B88-pharmaceuticals-06-00759]\]. Furthermore, Ca~v~2.3 ablation causes cardiac arhythmia and disturbances in autonomic cardiac control, suggesting that Ca~v~2.3 in pacemaker cells as well as in autonomic nerve endings may participate in cardiac signalling \[[@B101-pharmaceuticals-06-00759]\].

In future, more specific Ca~v~2.3 modualtors will be a key in establishing the exact role of Ca~v~2.3 in the physiological and pathophysiological processes, that it contributes to. Furthermore, recent evidence points to Ca~v~2.3 as a potential pharmacologic target in therapy of epilepsy, chronic pain, endocrine disturbances and vasospasms after subarchnoid hemmorhage. In this light, non-ion selective Ca~v~2.3 inhibitors with favourable pharmakokinetics could represent new therapeutic strategies for these disorders.
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